Ignite Creation Date:
2025-12-24 @ 10:02 PM
Ignite Modification Date:
2026-02-25 @ 6:53 PM
Study NCT ID:
NCT03448835
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-08
First Post:
2017-11-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Sponsor:
The Netherlands Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-07
Start Date Type:
ACTUAL
Primary Completion Date:
2026-10-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2017-11-22
First Submit QC Date:
None
Study First Post Date:
2018-02-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-04
Last Update Post Date:
2025-06-08
Last Update Post Date Type:
ACTUAL